KR101214364B1 - 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물 - Google Patents

수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물 Download PDF

Info

Publication number
KR101214364B1
KR101214364B1 KR1020110013167A KR20110013167A KR101214364B1 KR 101214364 B1 KR101214364 B1 KR 101214364B1 KR 1020110013167 A KR1020110013167 A KR 1020110013167A KR 20110013167 A KR20110013167 A KR 20110013167A KR 101214364 B1 KR101214364 B1 KR 101214364B1
Authority
KR
South Korea
Prior art keywords
eye
fusion protein
superoxide dismutase
protein
dry eye
Prior art date
Application number
KR1020110013167A
Other languages
English (en)
Korean (ko)
Other versions
KR20120093541A (ko
Inventor
최수영
김대원
이성호
박진서
음원식
Original Assignee
한림대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한림대학교 산학협력단 filed Critical 한림대학교 산학협력단
Priority to KR1020110013167A priority Critical patent/KR101214364B1/ko
Priority to PCT/KR2011/002394 priority patent/WO2012111878A1/fr
Publication of KR20120093541A publication Critical patent/KR20120093541A/ko
Application granted granted Critical
Publication of KR101214364B1 publication Critical patent/KR101214364B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020110013167A 2011-02-15 2011-02-15 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물 KR101214364B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020110013167A KR101214364B1 (ko) 2011-02-15 2011-02-15 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
PCT/KR2011/002394 WO2012111878A1 (fr) 2011-02-15 2011-04-06 Composition pharmaceutique contenant la protéine hybride de superoxyde dismutase, destinée à prévenir ou traiter les maladies des yeux

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110013167A KR101214364B1 (ko) 2011-02-15 2011-02-15 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물

Publications (2)

Publication Number Publication Date
KR20120093541A KR20120093541A (ko) 2012-08-23
KR101214364B1 true KR101214364B1 (ko) 2012-12-21

Family

ID=46672772

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020110013167A KR101214364B1 (ko) 2011-02-15 2011-02-15 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물

Country Status (2)

Country Link
KR (1) KR101214364B1 (fr)
WO (1) WO2012111878A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102531246B1 (ko) * 2021-12-23 2023-05-11 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 건성 황반변성의 예방 또는 치료용 용도
KR102593195B1 (ko) * 2021-12-27 2023-10-24 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 건성안의 예방 또는 치료용 용도
WO2023224136A1 (fr) * 2022-05-16 2023-11-23 주식회사 제노포커스 Superoxyde dismutase et ses utilisations pour la prévention ou le traitement de la rétinopathie diabétique ou de l'uvéite
KR102518033B1 (ko) * 2022-05-16 2023-04-05 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 당뇨망막병증 또는 포도막염의 예방 또는 치료용 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020010445A (ko) * 2000-07-26 2002-02-04 최수영 세포침투성 티에이티-슈퍼옥사이드 디스뮤테이스융합단백질 및 그 용도
PL210225B1 (pl) * 2001-12-14 2011-12-30 Alcon Zastosowanie związku naśladującego dysmutazę ponadtlenkową jako środka do leczenia zaburzeń i chorób oczu
KR100495140B1 (ko) * 2003-02-20 2005-06-14 학교법인 한림대학교 세포투과성 수송도메인 융합단백질과 그 용도
CN100558360C (zh) * 2003-11-20 2009-11-11 奥特拉控股公司 羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途
KR100815278B1 (ko) * 2006-07-25 2008-03-19 주식회사 케이티앤지 눈의 산화적 손상을 예방할 수 있는 건강기능식품 조성물

Also Published As

Publication number Publication date
KR20120093541A (ko) 2012-08-23
WO2012111878A1 (fr) 2012-08-23

Similar Documents

Publication Publication Date Title
KR101214362B1 (ko) Ｆｋ506 결합 단백질 융합 단백질을 함유하는 안과 질환 예방 및 치료용 점안제 조성물
US11759499B2 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
Vigneswara et al. Eye drop delivery of pigment epithelium-derived factor-34 promotes retinal ganglion cell neuroprotection and axon regeneration
US20210315890A1 (en) Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
US20170002043A1 (en) Novel peptides and methods and uses thereof for preventing retinal disorders
KR101214364B1 (ko) 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
KR20110020819A (ko) 안구건조증 및/또는 각막/결막 질환 치료용 약학 조성물
ES2715412T3 (es) Péptido derivado de SOCS1 para su uso en complicaciones crónicas de la diabetes
CN108350458A (zh) 用豹蛙酶和/或两栖酶治疗病毒性结膜炎
KR101906494B1 (ko) 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물
WO2013091164A1 (fr) Petite molécule polypeptidique destinée à prévenir et à limiter une inflammation et application de celle-ci
KR102646717B1 (ko) 세포 침투성 펩타이드와 fkbp12를 포함하는 융합 단백질 및 이의 용도
KR102593195B1 (ko) 수퍼옥시드 디스뮤타제 및 이의 건성안의 예방 또는 치료용 용도
JP7503590B2 (ja) 遺伝子構築物
JP7495230B2 (ja) 処置方法および新規構築物
JP2023536229A (ja) Ｎｇｆバリアント、産生、組成物、及び治療的使用
WO2008119850A1 (fr) Préparation topique pour le traitement de l'hypertension oculaire et du glaucome
CN114302734A (zh) PnPP-19用于预防和治疗眼病的方法和用途

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20151023

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20161007

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20170925

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20191114

Year of fee payment: 8